|Bid||2.2700 x 3200|
|Ask||2.2800 x 2200|
|Day's Range||1.9700 - 2.2800|
|52 Week Range||1.6700 - 17.6500|
|Beta (5Y Monthly)||4.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.38|
Last year, Ocugen (NASDAQ: OCGN) shares soared more than 700% over just a few days. The company signed an agreement to co-commercialize Bharat Biotech's coronavirus vaccine in the U.S. The companies later added rights in Canada to the agreement too. Bharat's product -- Covaxin -- already had gained emergency authorization in its home country of India.
The past 18 months have been a roller coaster for Ocugen (NASDAQ: OCGN). Shares of the biotech company skyrocketed in early 2021 after it announced an agreement with India-based Bharat Biotech. The deal stipulated that Ocugen would hold the right to commercialize the Covaxin coronavirus vaccine, which was originally developed by Bharat Biotech, in the U.S. and Canada.
With me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide a financial update. Earlier this morning, we issued a press release, including a business update and first-quarter financial results for 2022.